公开(公告)号：US20250051246A1

公开(公告)日：2025-02-13

申请号：US18799069

申请日：2024-08-09

Applicant: Pfizer Inc.

Inventor： Karen Jean COFFMAN ,  Dafydd Rhys OWEN ,  Matthew Richard REESE ,  Matthew Forrest SAMMONS ,  Raman SHARMA ,  Jamison Bryce TUTTLE ,  Qingyi YANG

IPC: C07B59/00 ,  A61K31/4025 ,  A61P31/14 ,  C07D403/12

Abstract: The invention relates to compounds of Formula (I) wherein Y1a, Y1b, Y2a, Y2b, Y2c, Y2d, Y2e, Y2f, Y2g, Y2h and Y2i are as defined herein and to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful in the treatment of coronavirus infections and coronavirus infection related disorders.

公开(公告)号：US20210355117A1

公开(公告)日：2021-11-18

申请号：US16492558

申请日：2018-03-06

Applicant: Pfizer Inc.

Inventor： Michael Aaron BRODNEY ,  Thomas Allen CHAPPIE ,  Jinshan Michael CHEN ,  Jotham Wadsworth COE ,  Karen Jean COFFMAN ,  Paul GALATSIS ,  Michelle Renee GARNSEY ,  Christopher John HELAL ,  Jaclyn Louise Henderson ,  Bethany Lyn KORMOS ,  Ravi G. KURUMBAIL ,  Luis Angel MARTINEZ-ALSINA ,  Martin Youngjin PETTERSSON ,  Matthew Richard REESE ,  Colin Richard ROSE ,  Antonia Friederike STEPAN ,  Patrick Robert VERHOEST ,  Travis T. WAGER ,  Joseph Scott WARMUS ,  Yuan ZHANG

IPC: C07D471/04

Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.